Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
(WorldNews Germany)

Ingelheim, Germany - 6th August, 2018 - Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC)-consisting of Imperial College London and the Universities of Oxford and Edinburgh-Imperial Innovations, and Oxford BioMedica (OXB) announce a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis (CF). The new partnership brings together the academic partners` leading expertise in developing gene therapy for CF and OXB`s leading expertise in manufacturing lentiviral vector-based therapies with Boehringer Ingelheim`s capabilities in drug discovery and the clinical development of novel breakthrough therapeutic agents. Cystic...